Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06486441 · ClinicalTrials.gov registry record · Phase 3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
A Phase 3 study of Endometrial Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
- 20
- Study locations
NCT06486441: Active Phase 3 study of Endometrial Cancer, sponsored by Gilead Sciences.
NCT06486441 is a Phase 3 study of Endometrial Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 640 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06486441, a Phase 3 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Primary Outcome
PFS, defined as the time from the date of randomization until the date of objective progressive disease (PD), as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever comes first.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Sacituzumab govitecan-hziy
Study Locations (20)
California
- City of Hope - Duarte
- UC San Diego Medical Center - La Jolla
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center - Los Angeles
- Stanford Women's Cancer Center - Palo Alto
- Kaiser Permanente Medical Center - Vallejo
Florida
- Florida Cancer Specialists - Fort Myers
- University of Florida - Gainesville
- Baptist MD Anderson Cancer Center - Jacksonville
Connecticut
- Hartford HealthCare Cancer Institute at Hartford Hospital - Hartford
- Yale University School of Medicine - New Haven
Georgia
- Winship Cancer Institute, Emory University - Atlanta
- Lewis Cancer & Research Pavilion at St. Joseph's/Candler Health System - Savannah
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
Kentucky
- Baptist Health Lexington - Lexington
- Norton Cancer Institute - Louisville
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
What the registry record for NCT06486441 still lists
NCT06486441 is an interventional study that assigns participants to a tested intervention. The registered 640 participants enrollment target is mid-sized for trials with a published cap, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (23% higher).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin is the first listed.
NCT06486441 names 20 study sites across 10 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06486441 about?
NCT06486441 is a clinical study titled "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)". The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives ...
What is the current status of trial NCT06486441?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2024-08-28. Estimated completion is 2029-06.
What conditions does trial NCT06486441 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06486441?
The interventions under investigation include: Doxorubicin (DRUG), Paclitaxel (DRUG), Sacituzumab govitecan-hziy (DRUG).
Who is sponsoring clinical trial NCT06486441?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06486441 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06486441's enrollment target sits among peer trials
640 23rd of 181 higher than 159 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
- NCT05156398 · 640 participants · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- NCT05930483 · 640 participants · NA
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI